The global ophthalmic drugs market size was exhibited at USD 34.19 billion in 2022 and is projected to hit around USD 72.53 billion by 2032, growing at a CAGR of 7.81% during the forecast period 2023 to 2032.
Key Pointers:
Ophthalmic Drugs Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 36.86 Billion |
|
Market Size by 2032 |
USD 72.53 Billion |
|
Growth Rate From 2023 to 2032 |
CAGR of 7.81% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
Drug Class, disease, route of administration, dosage form, product type |
|
Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
|
Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key Companies Profiled |
Novartis AG; Pfizer Inc.; Alcon; Allergan(AbbVie Inc); Merck & Co., Inc.; Bayer AG; Genentech, Inc.; Bausch Health Companies Inc.; Santen Pharmaceutical Co. Ltd.; Genentech, Inc (F. Hoffmann-La Roche Ltd); Coherus Biosciences, Inc. |
The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.
According to BrightFocus Foundation in 2022, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.
Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics’ EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.
Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA’s HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.
Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.
Drug Class Insights
The anti-VEGF agents dominated the ophthalmic drugs market and held the largest revenue share of 32.19% in 2022. The growth of the anti-VEGF agents segment is augmented by rising demand and adoption of anti-VEGF agents, and the presence of leading market players with robust product portfolios. For instance, LUCENTIS manufactured by Genentech USA is a prescription medicine for the treatment of patients with diabetic retinopathy, AMD, and myopic choroidal neovascularization. Further, the growth of the segment is also attributed to, the strong performance of Avastin, LUCENTIS, and others. The current class of anti-VEGF medications is effective but not long-lasting, hence the focus of players on the development of therapeutics with longer action is growing. Some of the companies with promising pipeline products include Opthea, Lupin Limited, and Kodiak Sciences Inc.
Anti-inflammatory agents are projected to grow at a steady pace of 8.9% owing to factors such as increasing incidence of ophthalmic conjunctivitis and recent product approvals. For instance, in February 2022, the U.S FDA approved the first generic of Restasis single-use vials for the treatment of inflammation associated with keratoconjunctivitis sicca. Anti-inflammatory drugs are basically classified into steroids and non-steroids. Some of the anti-inflammatory drugs commercialized in the U.S. are Xibrom, Voltaren, Prolensa, Ocufen, Nevanac, Ilevro, and Bromsite.
Disease Insights
The retinal disorder segment dominated the market and accounted for a revenue share of 35.14% in 2022 owing to factors such as the increasing prevalence of macular degeneration, and diabetic retinopathy. For instance, in 2022, According to amplify eye care, it was estimated that almost 11 million patients had some form of AMD in 2021, and is expected to reach 22 million by 2050. Moreover, the increasing sales volume of ophthalmic drugs and the presence of innovative pipeline drugs are likely to bolster segment demand. The increasing funding for developing treatments in the segment is boosting the market growth. For instance, in September 2022, Trinity Researchers received funding of USD 3.14 million for the development of treatment for the condition in collaboration with companies such as Eli Lilly and Roche.
In addition, the infection segment is expected to experience steady growth of 8.1% during the forecast period. The growth of the infection segment is accounted for high incidences of eye infections such as conjunctivitis, swollen eye, and others. Moreover, increasing awareness of eye infections is projected to accelerate segment demand. The entry of biosimilar drugs in the segment is projected to intensify competition in the market. For instance, Polyhexanide, by SIFI for parasitic eye infection is expected to be launched in 2022 as the Biosimilar Aflibercept in the European Union.
Dosage Form Insights
The eye drops segment held the largest revenue share of 39.13% in 2022. The growth of the eye drop segment is governed by rising OTC availability of eye drops, patient compliance factors, and a high incidence of eye disorders. Moreover, novel product launches with formulation modifications are also anticipated to cater to segment demand. For instance, in January 2022, Alcon announced the launch of its novel systane complete preservative-free eye drop.
In addition, the presence of novel technology to enhance bioavailability and physiochemical stability is anticipated to propel segment demand. For instance, in July 2021, Bosch and Lomb announced the U.S. launch of Biotrue, hydration lubricant eye drops. This product is derived from a natural source and is preservative free.
Ophthalmic gels are applied directly to the eyelids or the periphery of the eye. Gels are available as viscous liquids that are used to treat uveitis, chronic inflammation, and cataracts. Aqueous gel formulations utilizing hydrophilic polymers and stimuli-responsive polymers remain key attractions for investment in this market. Gels enable the incorporation of pharmaceutical drugs for achieving the desired therapeutic effect and bioactivity at specific ocular sites. Increased entry of over-the-counter products in the segment is creating intense competitive rivalry.
Product Type Insights
The prescription drugs segment held the largest revenue share of 58.18% in 2022 and is to expected to maintain its dominance throughout the forecast period. The growth of the prescription drugs segment is accounted for by the rising prevalence of disorders such as AMD, and diabetes retinopathy. Moreover, improved efficacy and better safety are some of the factors that are likely to boost prescription segment demand. Some of the drugs present in this market include Lotemax gel/ointment, Zylet, Durezol, Bepreve (bepotastine besilate ophthalmic solution), and prescription artificial tears. Bepreve is an antihistamine used to treat allergic conjunctivitis. Some prescription products contain moisturizing and lubricating agents that enhance the secretion of tears temporarily. Prescription products are considered most effective for treating ophthalmic disorders and are preferred over OTC products.
Whereas, OTC drugs segment is expected to grow at a steady rate of 8.6% owing to factors such as easy patient access, the surge in e-pharmacies, and rising product launches of OTC eye drops. For instance, in April 2022 Théa Pharma Inc announced the commercial availability of iVIZIA line of OTC eye care products in the U.S. They are commercially available in various dosage forms including gels, emulsions, capsules, ointment, and eye drops. Some of the most commonly prescribed OTC products include Alaway (Bausch & Lomb, Inc.); Zaditor (Alcon, Inc.); Otrivine-Antistin (Novartis Consumer Health); Brolene (Sanofi); Golden Eye Ointment (Sigma Pharmaceuticals); GelTears (Bausch & Lomb); and Viscotears (Alcon, Inc.).
Route of Administration Insights
The topical route of administration has dominated the ophthalmic drugs market in 2022 and is likely to maintain its lead throughout the forecast period. The growth of the topical segment is accounted for by increasing demand for topical products due to convenient dosage, patient compliance factors, and various strategic initiatives undertaken by market players. Topical drug dosage forms generally include suspensions, solutions, and ointments. The cornea is the primary route of topical absorption that pose significant anatomical barriers. The availability of several drugs delivered via the topical route of administration is estimated to be the major driver of this segment. For instance, in October 2021, Allergan an AbbVie Inc company announced that U.S. FDA has approved VUITY for the treatment of presbyopia. Vuity is the only FDA-approved eye drop to treat various eye conditions.
Intraocular delivery route facilitates direct entry of drugs into the blood-retinal barrier and, therefore, highest peak of drug concentration can be achieved. It achieves maximum intraocular bioavailability in posterior segment tissues of the eye, such as cone-containing fovea or macula. In May 2022, Vabysmo injection was launched by Chugai Pharmaceutical Co., Ltd. for the treatment of AMD. However, this is the most invasive route of administration, involving penetration of drugs in the eye and, thus, is not free of injection-related complications.
Regional Insights
In 2022, North America led the ophthalmic drugs market and held the largest revenue share of 39.15%. The growth of the region is accounted for a higher prevalence of eye diseases, and rising awareness about eye diseases. Moreover, increasing research and development by leading players is also anticipated to fuel regional growth. Furthermore, the presence of leading players like Alcon, Pfizer Inc, and Bausch and Lomb. For instance, in June 2022, Harrow Health Inc announced that MAXITROL and IOPIDINE 1% are commercially available in the U.S. The new guidelines by the FDA, under the Prescription Drug User Fee Act, provide a structured approach to assess the risks and benefits in clinical trials for these ophthalmic drugs.
Asia Pacific is expected to be the fastest-growing region with a CAGR of 9.7%. The growth of the Asia pacific region is attributed to the presence of a large patient pool, high disease prevalence, and the emergence of local companies. The Asia Pacific region has the highest patient base, however, the treatment rate is the lowest in the region. Moreover, various strategic initiatives undertaken by market players are also expected to boost regional growth. For instance, in June 2020 Otsuka Pharmaceutical Co., Ltd., and Senju Pharmaceutical Co., Ltd. announced the launch of a combination ophthalmic solution, AILAMIDE for the treatment of ocular hypertension and glaucoma.
Some of the prominent players in the Ophthalmic Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Ophthalmic Drugs market.
By Drug Class
By Disease
By Dosage Form
By Route of Administration
By Product Type
By Region
Chapter 1 Ophthalmic Drugs Market: Methodology And Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 3: Country Wise Market Estimation Using Top Down Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Ophthalmic Drugs Market: Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Ophthalmic Drugs Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.2 Regulatory Framework
3.2.1 Regulatory Bodies, By Region
3.2.2 North America
3.2.3 Europe
3.2.4 Asia Pacific
3.2.5 Latin America
3.2.6 Middle East & Africa
3.3 Patent Expiry Analysis
3.4 Pipeline Analysis
3.4.1 Pipeline Analysis, By Phase (Funder Type- Industry)
3.4.2 Pipeline Analysis, By Phase (Funder Type- All Others)
3.5 Cost Structure Analysis
3.6 Market Dynamics
3.6.1 Market Drivers Analysis
3.6.1.1 Increasing Disease Prevalence
3.6.1.2 Strong Developmental Pipeline
3.6.1.3 Advancements In Drug Delivery
3.6.1.4 Promising Investment Scenario
3.6.2 Market Restraint Analysis
3.6.2.1 Patent Expiry Of Blockbuster Drugs
3.7 Penetration & Growth Prospect Mapping
3.8 Ophthalmic Drugs: Market Analysis Tools
3.8.1 Industry Analysis - Porter’s
3.8.2 Pestle Analysis
3.8.3 Major Deals And Strategic Alliances
3.8.3.1 New Product Launch
3.8.3.2 Acquisition
3.8.3.3 Expansion
3.8.3.4 Partnerships
3.8.3.5 Marketing & Promotions
3.9 Primary Research Analysis
3.9.1 Market Scenario
3.9.2 Key Kol Responses
Chapter 4 Ophthalmic Drugs Market: Segment Analysis, By Drug Class, 2020 - 2032
4.1 Definition and Scope
4.2 Drug Class Market Share Analysis, 2023 & 2032
4.3 Segment Dashboard
4.4 Global Ophthalmic Drugs Market, by Drug Class, 2020 - 2032
4.5 Market Size & Forecasts and Trend Analyses, 2020 - 2032
4.5.1 Antiallergy
4.5.1.1 Antiallergy Market, 2020 - 2032
4.5.2 Anti-Vegf Agents
4.5.2.1 Anti-Vegf Agents Market, 2020 - 2032
4.5.3 Anti-Inflammatory
4.5.3.1 Anti-Inflammatory Market, 2020 - 2032
4.5.3.2 Non-Steroidal Anti-Inflammatory Drugs
4.5.3.2.1 Non-Steroidal Anti-Inflammatory Market, 2020 - 2032
4.5.3.3 Steroidal Anti-Inflammatory Drugs
4.5.3.3.1 Steroidal Anti-Inflammatory Market, 2020 - 2032
4.5.4 Antiglaucoma
4.5.4.1 Antiglaucoma Market, 2020 - 2032
4.5.5 Others
4.5.5.1 Others Market, 2020 - 2032
Chapter 5 Ophthalmic Drugs Market: Segment Analysis, By Disease, 2020 - 2032
5.1 Definition and Scope
5.2 Disease Market Share Analysis, 2023 & 2032
5.3 Segment Dashboard
5.4 Global Ophthalmic Drugs Market, by Disease, 2020 - 2032
5.5 Market Size & Forecasts and Trend Analyses, 2020 - 2032
5.5.1 Dry Eye
5.5.1.1 Dry Eye Market, 2020 - 2032
5.5.2 Eye Allergies
5.5.2.1 Eye Allergies Market, 2020 - 2032
5.5.3 Glaucoma
5.5.3.1 Glaucoma Market, 2020 - 2032
5.5.4 Eye Infection
5.5.4.1 Eye Infection Market, 2020 - 2032
5.5.5 Retinal Disorders
5.5.5.1 Retinal Disorders Market, 2020 - 2032
5.5.5.2 Macular Degeneration
5.5.5.2.1 Macular Degeneration Market, 2020 - 2032
5.5.5.3 Diabetic Retinopathy
5.5.5.3.1 Diabetic Retinopathy Market, 2020 - 2032
5.5.5.4 Others
5.5.5.4.1 Others Market, 2020 - 2032
5.5.6 Uveitis
5.5.6.1 Uveitis Market, 2020 - 2032
5.5.7 Others
5.5.7.1 Others Market, 2020 - 2032
Chapter 6 Ophthalmic Drugs Market: Segment Analysis, By Route of Administration, 2020 - 2032
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2023 & 2032
6.3 Segment Dashboard
6.4 Global Ophthalmic Drugs Market, by Route of Administration, 2020 - 2032
6.5 Market Size & Forecasts and Trend Analyses, 2020 - 2032
6.5.1 Topical
6.5.1.1 Topical Market, 2020 - 2032
6.5.2 Local Ocular
6.5.2.1 Local Ocular Market, 2020 - 2032
6.5.2.2 Subconjunctival
6.5.2.2.1 Subconjunctival Market, 2020 - 2032
6.5.2.3 Intravitreal
6.5.2.3.1 Intravitreal Market, 2020 - 2032
6.5.2.4 Retrobulbar
6.5.2.4.1 Retrobulbar Market, 2020 - 2032
6.5.2.5 Intracameral
6.5.2.5.1 Intracameral Market, 2020 - 2032
6.5.3 Systemic
6.5.3.1 Systemic Market, 2020 - 2032
Chapter 7 Ophthalmic Drugs Market: Segment Analysis, By Dosage Form, 2020 - 2032
7.1 Definition and Scope
7.2 Dosage Form Market Share Analysis, 2023 & 2032
7.3 Segment Dashboard
7.4 Global Ophthalmic Drugs Market, by Dosage Form, 2020 - 2032
7.5 Market Size & Forecasts and Trend Analyses, 2020 - 2032
7.5.1 Gels
7.5.1.1 Gels Market, 2020 - 2032
7.5.2 Eye Solutions And Suspensions
7.5.2.1 Eye Solutions And Suspensions Market, 2020 - 2032
7.5.3 Capsules & Tablets
7.5.3.1 Capsules & Tablets Market, 2020 - 2032
7.5.4 Eye Drops
7.5.4.1 Eye Drops Market, 2020 - 2032
7.5.5 Ointments
7.5.5.1 Ointments Market, 2020 - 2032
Chapter 8 Ophthalmic Drugs Market: Segment Analysis, By Product Type, 2020 - 2032
8.1 Definition and Scope
8.2 Product Type Market Share Analysis, 2023 & 2032
8.3 Segment Dashboard
8.4 Global Ophthalmic Drugs Market, by Product Type, 2020 - 2032
8.5 Market Size & Forecasts and Trend Analyses, 2020 - 2032
8.5.1 Otc Drugs
8.5.1.1 Otc Drugs Market, 2020 - 2032
8.5.2 Prescription Drugs
8.5.2.1 Prescription Drugs Market, 2020 - 2032
Chapter 9 Ophthalmic Drugs Market: Segment Analysis, By Region, 2020 - 2032
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2023 & 2032
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 Regional Market Share and Leading Players, 2023
9.5.1 North America
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Latin America
9.5.5 Middle East & Africa
9.6 Swot Analysis
9.6.1 North America
9.6.2 Europe
9.6.3 Asia Pacific
9.6.4 Latin America
9.6.5 Middle East & Africa
9.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2023 - 2032
9.7.1 North America
9.7.1.1 North America Ophthalmic Drugs Market, 2020-2032
9.7.1.2 U.S.
9.7.1.2.1 U.S. Ophthalmic Drugs Market, 2020 - 2032
9.7.1.3 Canada
9.7.1.3.1 Canada Ophthalmic Drugs Market, 2020 - 2032
9.7.2 Europe
9.7.2.1 Europe Ophthalmic Drugs Market, 2020 - 2032
9.7.2.2 UK
9.7.2.2.1 UK Ophthalmic Drugs Market, 2020 - 2032
9.7.2.3 Germany
9.7.2.3.1 Germany Ophthalmic Drugs Market, 2020 - 2032
9.7.2.4 France
9.7.2.4.1 France Ophthalmic Drugs Market, 2020 - 2032
9.7.2.5 Italy
9.7.2.5.1 Italy Ophthalmic Drugs Market, 2020 - 2032
9.7.2.6 Spain
9.7.2.6.1 Spain Ophthalmic Drugs Market, 2020 - 2032
9.7.2.7 Russia
9.7.2.7.1 Russia Ophthalmic Drugs Market, 2020 - 2032
9.7.3 Asia PacificC
9.7.3.1 Asia Pacific Ophthalmic Drugs Market, 2020 - 2032
9.7.3.2 Japan
9.7.3.2.1 Japan Ophthalmic Drugs Market, 2020 - 2032
9.7.3.3 China
9.7.3.3.1 China Ophthalmic Drugs Market, 2020 - 2032
9.7.3.4 India
9.7.3.4.1 India Ophthalmic Drugs Market, 2020 - 2032
9.7.3.5 Australia
9.7.3.5.1 Australia Ophthalmic Drugs Market, 2020 - 2032
9.7.3.6 South Korea
9.7.3.6.1 South Korea Ophthalmic Drugs Market, 2020 - 2032
9.7.3.7 Singapore
9.7.3.7.1 Singapore Ophthalmic Drugs Market, 2020 - 2032
9.7.4 Latin America
9.7.4.1 Latin America Ophthalmic Drugs Market, 2020 - 2032
9.7.4.2 Mexico
9.7.4.2.1 Mexico Ophthalmic Drugs Market, 2020 - 2032
9.7.4.3 Brazil
9.7.4.3.1 Brazil Ophthalmic Drugs Market, 2020 - 2032
9.7.4.4 Argentina
9.7.4.4.1 Argentina Ophthalmic Drugs Market, 2020 - 2032
9.7.5 Middle East & Africa
9.7.5.1 Middle East & Africa Ophthalmic Drugs Market, 2020 - 2032
9.7.5.2 South Africa
9.7.5.2.1 South Africa Ophthalmic Drugs Market, 2020 - 2032
9.7.5.3 UAE
9.7.5.3.1 UAE Ophthalmic Drugs Market, 2020 - 2032
9.7.5.4 Saudi Arabia
9.7.5.4.1 Saudi Arabia Ophthalmic Drugs Market, 2020 - 2032
Chapter 10 Ophthalmic Drugs Market: Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 Ansoff Matrix
10.1.2 Heat Map Analysis
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List Of Key Distributors And Channel Partners
10.3.2 Key Customers
10.3.3 Key Company Market Share Analysis, 2023
10.4 Public Companies
10.4.1 Company Market Position Analysis
10.4.2 Company Market Share, By Region
10.4.3 Competitive Dashboard Analysis
10.4.3.1 Market Differentiators
10.5 Private Companies
10.5.1 List Of Key Emerging Companies
10.5.2 Regional Network Map
10.5.3 Company Market Position Analysis
10.6 Company Profiles
10.6.1 ALCON
10.6.1.1 Company Overview
10.6.1.2 Financial Performance
10.6.1.3 Product Benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 NOVARTIS AG
10.6.2.1 Company Overview
10.6.2.2 Financial Performance
10.6.2.3 Product Benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 JOHNSON & JOHNSON SERVICES, INC.
10.6.3.1 Company Overview
10.6.3.2 Financial Performance
10.6.3.3 Product Benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 BAUSCH HEALTH
10.6.4.1 Company Overview
10.6.4.2 Financial Performance
10.6.4.3 Product Benchmarking
10.6.4.4 Strategic Initiatives
10.6.5 MERCK & CO. INC.
10.6.5.1 Company Overview
10.6.5.2 Financial Performance
10.6.5.3 Product Benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 REGENERON PHARMACEUTICALS, INC.
10.6.6.1 Company Overview
10.6.6.2 Financial Performance
10.6.6.3 Product Benchmarking
10.6.6.4 Strategic Initiatives
10.6.7 COHERUS BIOSCIENCES, INC.
10.6.7.1 Company Overview
10.6.7.2 Financial Performance
10.6.7.3 Product Benchmarking
10.6.7.4 Strategic Initiatives
10.6.8 ALLERGAN
10.6.8.1 Company Overview
10.6.8.2 Financial Performance
10.6.8.3 Product Benchmarking
10.6.8.4 Strategic Initiatives
10.6.9 PFIZER, INC.
10.6.9.1 Company Overview
10.6.9.2 Financial Performance
10.6.9.3 Product Benchmarking
10.6.9.4 Strategic Initiatives
10.6.10 BAYER AG
10.6.10.1 Company Overview
10.6.10.2 Financial Performance
10.6.10.3 Product Benchmarking
10.6.10.4 Strategic Initiatives
10.6.11 SANTEN PHARMACEUTICALS CO. LTD.
10.6.11.1 Company Overview
10.6.11.2 Financial Performance
10.6.11.3 Product Benchmarking
10.6.11.4 Strategic Initiatives
10.6.12 GENETECH, INC.
10.6.12.1 Company Overview
10.6.12.2 Financial Performance
10.6.12.3 Product Benchmarking
10.6.12.4 Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers